Ensitrelvir Patent Expiration
Ensitrelvir was first introduced by Shionogi Inc
Ensitrelvir Patents
Given below is the list of patents protecting Ensitrelvir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xocova | US11814368 | Triazine Derivatives Having Virus Replication Inhibitory Activity And Pharmaceutical Composition Comprising The Same | May 01, 2042 | Shionogi |
| Xocova | US12559474 | Triazine Derivatives Having Virus Replication Inhibitory Activity And Pharmaceutical Composition Comprising The Same | May 01, 2042 | Shionogi |
| Xocova | US9150546 | Triazine Derivative And Pharmaceutical Composition Comprising The Same | Dec 12, 2030 | Shionogi |
Ensitrelvir's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ensitrelvir:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir) | University of Minnesota | NA |
TERMINATED
(Aug 1, 2026)
| PHASE3 |